Brief: Biosergen Pauses Development Of Bsg005
04/04/2026 20:01
April 4 (Reuters) - Biosergen AB BIOSGN.ST: BIOSERGEN PAUSES DEVELOPMENT OF BSG005 BIOSERGEN AB - ESTIMATED CAPITAL INJECTION OF SEK 60 MILLION REQUIRED, NOT CONSIDERED FEASIBLE Source text: ID:nWkrb8kJ3Z Further company coverage: BIOSGN.ST ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biosergen AB
See all newsBrief: Nasdaq Approves Biosergen's Delisting Application
Brief: Biosergen Applies For Delisting Of The Company's Shares From Nasdaq First North Growth Market Conditional Upon Completion Of The Merger With Flerie
Brief: Biosergen Resolves On Set-Off Issue
Brief: Biosergen Rights Issue Oversubscribed
Brief: Biosergen Reports H1 EBITDA Of SEK -10.5 Million